Compare iShares MSCI Canada (TSX) (EWC) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares MSCI Canada (TSX) trades at $59.18 (market cap $7.22B), while Spyre Therapeutics Inc. Common Stock trades at $78.4 (market cap $7.35B). The key difference: iShares MSCI Canada (TSX) and Spyre Therapeutics Inc. Common Stock are close in size by market cap, and Spyre Therapeutics Inc. Common Stock is more actively traded (1,624,631 versus 1,285,678). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Canada (TSX) for 57 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| EWC | SYRE | |
|---|---|---|
Market Cap | $7.22B | $7.35B |
Volume | 1,285,678 | 1,624,631 |
Sector | Broad Market / Factor | Health |
52-Week High | $62.64 | $108.92 |
52-Week Low | $49.72 | $22.18 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC is trading at $59.91, up 0.77% with a bullish technical signal supported by moving averages. The stock shows neutral oscillator readings with RSI at balanced levels. Recent news highlights significant trade tensions between Canada and the US, with potential EU associate membership discussions creating both opportunities and risks for Canadian-focused investments.
The outlook remains cautiously optimistic given technical strength, but fundamental metrics are unavailable. Key risks include US-Canada trade war escalation and geopolitical uncertainties. Investors should monitor trade negotiations and economic data for directional cues on this Canada-focused equity.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
